• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Resuming oral anticoagulant (OAC) therapy after an OAC-related bleed associated with higher rates of bleeding

byDavy LauandAlex Chan
March 12, 2021
in Cardiology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

2 Minute Medicine Rewind February 6, 2023

Dual antiplatelet therapy discontinued 9 months after percutaneous coronary intervention associated with improved morbidity and mortality

#VisualAbstract: Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

1. Resuming oral anticoagulant (OAC) therapy after an OAC-related bleed was associated with higher rates of subsequent bleeding, but lower rates of thrombosis and all-cause mortality.  

Evidence Rating Level: 2 (Good)

While oral anticoagulants (OACs) are used to prevent thrombosis, a common adverse side effect with OAC usage is bleeding. A clinical dilemma occurs when deciding whether or not to resume OACs after a bleed. Past research has shown that 50% and 64% of patients permanently stopped OAC usage after a gastrointestinal (GI) and intracranial bleed respectively. As well, previous studies have focused more on warfarin use after bleeding, and not so much on direct OACs (DOACs), which are the primary preventative measure for stroke due to atrial fibrillation. Therefore, the current study aimed to compare bleeding, thrombosis, and all-cause mortality outcomes between patients who did or did not resume OACs, after a bleeding event related to OAC use. Data was gathered between 2012 and 2017 from patients aged 66 years and older, who had a hospital admission related to bleeding, and a prescription for an OAC within 100 days prior to admission. Of the 6793 patients in the study, 70.5% of patients resumed using an OAC within a year of admission (71.6% for GI bleed, and 45.6% for intracranial hemorrhage). For all categories of bleed, there was a lower rate of thrombosis for those who resumed OACs (10.0% vs 14.9%, adjusted hazards ratio 0.60, 95% CI 0.50-0.72). However, the rates of bleeding were higher in those who resumed OACs (35.2% vs 16.4%, adjusted HR 1.88, 95% CI 0.48-0.60). Additionally, there was a lower rate of mortality for those who resumed OACs (31% vs 54%, adjusted HR 0.54, 95% CI 0.48-0.60). These findings were generally consistent across GI bleeds, intracranial hemorrhage, and extracranial non-GI bleeds, although the rate of thrombosis for intracranial hemorrhage patients resuming OACs was no different from those who did not resume (HR 0.73, 95% CI 0.44-1.23). Overall, resumption of OACs after an OAC-related bleed was shown to reduce thrombosis and all-cause mortality rates significantly.

Click to read the study in CMAJ

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiologythrombosis
Previous Post

Study details societal costs of a measles outbreak

Next Post

2 Minute Medicine Rewind March 15, 2021

RelatedReports

Prevalence of hypertension among adolescents varies by race and BMI
Weekly Rewinds

2 Minute Medicine Rewind February 6, 2023

February 6, 2023
Drug-coated balloons are noninferior to drug-eluting stents for treatment of small vessel coronary artery disease
Cardiology

Dual antiplatelet therapy discontinued 9 months after percutaneous coronary intervention associated with improved morbidity and mortality

February 4, 2023
#VisualAbstract: Aspirin thromboprophylaxis noninferior to low-molecular-weight heparin in patients with fractures
StudyGraphics

#VisualAbstract: Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

February 3, 2023
Antiarrhythmic drugs have no survival benefit in shock-refractory out-of-hospital cardiac arrest
Cardiology

Extracorporeal CPR and conventional CPR similarly improve cardiac arrest survival

February 2, 2023
Next Post
Prescription of antibiotics for acute respiratory infections increasing

2 Minute Medicine Rewind March 15, 2021

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children

Attributes and predictors of long COVID

Provision of medically-tailored meals linked with lower admissions and medical spending

South European Atlantic Diet associated with lower all-cause mortality

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Momelotinib reduces symptom burden compared to danazol in patients with myelofibrosis
  • Machine renal perfusion reduces delayed graft function after transplantation
  • COVID-19 mRNA vaccines are safe and effective in children aged 5 to 11 years
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options